Growth factors, cytokines, and hormones promote both the proliferation and the survival of immature cells of the bone marrow that are destined to become blood cells. When these growth factors are down-regulated in normal ways to prevent overproduction of blood cells, factor-dependent immature blood cells will stop proliferating and die through a self imposed """"""""suicide"""""""" that is referred to as apoptosis or programmed cell death. The central hypothesis of this proposal is that the AP1 transcription factor, JunB, acts as an activator of apoptosis and/or a suppresser of proliferation when erythropoietin (EPO) is withdrawn from erythroid cells that require the hormone for survival and proliferation. JunB is not expressed in cells cultured in EPO, but JunB mRNA and JunB protein are induced following EPO withdrawal. In the first specific aim, JunB will be overexpressed to test if the presence of JunB in erythroid cells that do not normally express this factor a) induces apoptosis, b) regulates the expression and activity of pro- and anti-apoptotic signaling molecules Bcl-XL, Bcl-2, BAD, BAX; or c) suppresses proliferation by modulating the cell cycle. Bcl-XL is the primary anti-apoptotic regulator of survival in EPO-dependent erythroid cells. The loss of an intracellular kinase activity that allows BAD to inactivate Bcl-XL survival activity is important in triggering apoptosis. The notion that the ratio of BAD to Bcl-XL is more of a critical factor in regulating apoptosis than signals that regulate BAD phosphorylation will be tested by increasing the ratio of BAD to Bcl-XL in cells. In the second specific aim, dominant negative forms of P13-kinase in HCD57 cells will be expressed to test if an EPO-independent, P13-kinase dependent pathway promotes leukemia by inducing a reversible, pre-apoptotic state when EPO is withdrawn. The ratio of BAD to Bcl-XL expression will be compared in primary murine erythroid cells (FVA), primary human erythroid cells, and murine leukemic cells to see if the increased susceptibility of mature erythroid cells to undergo apoptosis after growth factor withdrawal is due to the increased ratio of BAD to Bcl-XL. Jun N-terminal Kinase (JNK) promotes survival and/or proliferation signals by activating the AP1 transcription factor c-Jun. In the third specific aim, a dominant negative form of JNK will be expressed to define the role of JNK in EPO signaling. EPO-dependent activation of JNK through the secretion of an autocrine factor will be tested.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL065906-04
Application #
6638704
Study Section
Hematology Subcommittee 2 (HEM)
Program Officer
Qasba, Pankaj
Project Start
2000-05-17
Project End
2005-04-30
Budget Start
2003-05-01
Budget End
2005-04-30
Support Year
4
Fiscal Year
2003
Total Cost
$253,750
Indirect Cost
Name
Virginia Commonwealth University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Abutin, Randolph M; Chen, Jingchun; Lung, Tina K et al. (2009) Erythropoietin-induced phosphorylation/degradation of BIM contributes to survival of erythroid cells. Exp Hematol 37:151-8
Gewirtz, David A; Di, Xu; Walker, Teneille D et al. (2006) Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs. Clin Cancer Res 12:2232-8
Jacobs-Helber, Sarah M; Sawyer, Stephen T (2004) Jun N-terminal kinase promotes proliferation of immature erythroid cells and erythropoietin-dependent cell lines. Blood 104:696-703
Chen, Jingchun; Jacobs-Helber, Sarah M; Barber, Dwayne L et al. (2004) Erythropoietin-dependent autocrine secretion of tumor necrosis factor-alpha in hematopoietic cells modulates proliferation via MAP kinase--ERK-1/2 and does not require tyrosine docking sites in the EPO receptor. Exp Cell Res 298:155-66
Jacobs-Helber, Sarah M; Roh, Kwan-Ho; Bailey, Daniel et al. (2003) Tumor necrosis factor-alpha expressed constitutively in erythroid cells or induced by erythropoietin has negative and stimulatory roles in normal erythropoiesis and erythroleukemia. Blood 101:524-31
Jacobs-Helber, Sarah M; Abutin, Randolph M; Tian, Cuixia et al. (2002) Role of JunB in erythroid differentiation. J Biol Chem 277:4859-66
Koury, Mark J; Sawyer, Stephen T; Brandt, Stephen J (2002) New insights into erythropoiesis. Curr Opin Hematol 9:93-100